⚠ COVID-19 INFORMATION: Vaccine Information, Other Resources 

High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes

Rossoff, J.; Tse, W. T.; Duerst, R. E.; Schneiderman, J.; Morgan, E.; Kletzel, M.; Chaudhury, S.

Pediatr Hematol Oncol. 2019 Jan 27; 1-6


Wilms tumor (WT) treatment regimens are curative for more than 80% of patients, but those with relapsed or refractory disease continue to have poor outcomes. High-dose chemotherapy followed by autologous stem cell rescue is often utilized although outcomes remain variable. We report on HD-ASCR outcomes in 24 patients with relapsed or refractory Wilms tumor. Three-year disease free and overall survival are 46% and 60%, respectively, which is similar to those reported for conventional salvage therapies. These outcomes suggest that conventional salvage therapies should be employed for relapsed and refractory WT rather than HD-ASCR.

Read More on PubMed